Huldrych F Gunthard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2942086/publications.pdf

Version: 2024-02-01

		5782	8212
440	29,247	84	153
papers	citations	h-index	g-index

471	471	471	24377
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia. Science, 1997, 278, 1291-1295.	6.0	2,071
2	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2012, 308, 387-402.	3.8	1,239
3	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	0.6	1,056
4	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2010, 304, 321.	3.8	732
5	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	6.3	627
6	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA - Journal of the American Medical Association, 2016, 316, 191.	3.8	533
7	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA - Journal of the American Medical Association, 2018, 320, 379.	3.8	486
8	Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine, 2005, 11, 615-622.	15.2	468
9	Antiretroviral Drug Resistance Testing in Adult HIVâ€1 Infection: 2008 Recommendations of an International AIDS Societyâ€“USA Panel. Clinical Infectious Diseases, 2008, 47, 266-285.	2.9	428
10	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2014, 312, 410.	3.8	428
11	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	1.5	377
12	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
13	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1651.	3.8	329
14	Cohort Profile: The Swiss HIV Cohort Study. International Journal of Epidemiology, 2010, 39, 1179-1189.	0.9	322
15	Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy. JAMA - Journal of the American Medical Association, 2001, 286, 171.	3.8	312
16	Early and nonreversible decrease of CD161++/MAIT cells in HIV infection. Blood, 2013, 121, 951-961.	0.6	307
17	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. PLoS Pathogens, 2012, 8, e1002529.	2.1	306
18	Effect of Treatment, during Primary Infection, on Establishment and Clearance of Cellular Reservoirs of HIV-1. Journal of Infectious Diseases, 2005, 191, 1410-1418.	1.9	294

#	Article	IF	Citations
19	HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16725-16730.	3.3	273
20	Differences in HIV Burden and Immune Activation within the Gut of HIVâ€Positive Patients Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 202, 1553-1561.	1.9	262
21	Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12574-12579.	3.3	240
22	Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals. Clinical Pharmacology and Therapeutics, 2007, 81, 557-566.	2.3	240
23	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clinical Infectious Diseases, 2012, 55, 1408-1416.	2.9	225
24	Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4819-4824.	3.3	224
25	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 565-575.	4.6	217
26	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 409-417.	4.6	216
27	Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. Aids, 2010, 24, 2451-2460.	1.0	210
28	2011 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2011, 19, 156-64.	0.1	207
29	Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 2012, 29, 347-357.	3.5	206
30	Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10948-10953.	3.3	205
31	Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. Frontiers in Microbiology, 2012, 3, 329.	1.5	204
32	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13747-13752.	3.3	199
33	Update of the drug resistance mutations in HIV-1: March 2013. Topics in Antiviral Medicine, 2013, 21, 6-14.	0.1	197
34	Life expectancy in HIV-positive persons in Switzerland. Aids, 2017, 31, 427-436.	1.0	193
35	Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies. PLoS Pathogens, 2012, 8, e1002634.	2.1	189
36	Minority Quasispecies of Drugâ€Resistant HIVâ€1 That Lead to Early Therapy Failure in Treatmentâ€Naive and â€Adherent Patients. Clinical Infectious Diseases, 2009, 48, 239-247.	2.9	188

#	Article	IF	Citations
37	Gilbert Syndrome and the Development of Antiretroviral Therapyâ€“Associated Hyperbilirubinemia. Journal of Infectious Diseases, 2005, 192, 1381-1386.	1.9	182
38	2014 Update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2014, 22, 642-50.	0.1	173
39	Molecular Epidemiology Reveals Longâ€Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. Journal of Infectious Diseases, 2010, 201, 1488-1497.	1.9	172
40	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	3.9	168
41	Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. Aids, 2000, 14, 31-36.	1.0	160
42	Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals. PLoS Pathogens, 2010, 6, e1000781.	2.1	158
43	Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Societyâ€“USA Panel. Clinical Infectious Diseases, 2019, 68, 177-187.	2.9	156
44	A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 2003, 163, 1220.	4.3	153
45	Dynamics of Total, Linear Nonintegrated, and Integrated HIVâ€1 DNA In Vivo and In Vitro. Journal of Infectious Diseases, 2008, 197, 411-419.	1.9	149
46	Residual Human Immunodeficiency Virus (HIV) Type 1 RNA and DNA in Lymph Nodes and HIV RNA in Genital Secretions and in Cerebrospinal Fluid after Suppression of Viremia for 2 Years. Journal of Infectious Diseases, 2001, 183, 1318-1327.	1.9	146
47	Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1polfrom Clinical Samples. AIDS Research and Human Retroviruses, 1998, 14, 869-876.	0.5	140
48	Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy. Journal of Virology, 2005, 79, 1772-1788.	1.5	136
49	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 622-635.	4.6	135
50	24 Hours in the Life of HIV-1 in a T Cell Line. PLoS Pathogens, 2013, 9, e1003161.	2.1	134
51	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 2009, 19, 300-309.	0.7	133
52	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	15.2	133
53	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2002, 185, 1251-1260.	1.9	132
54	2017 Update of the Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine, 2016, 24, 132-133.	0.1	132

#	Article	IF	Citations
55	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 2009, 49, 1069-1082.	3.6	131
56	Role of retroviral restriction factors in the interferon-Î±â€“mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.	3.3	129
57	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	2.9	127
58	2019 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2019, 27, 111-121.	0.1	127
59	Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. Nucleic Acids Research, 2014, 42, e115-e115.	6.5	126
60	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. ELife, 2013, 2, e01123.	2.8	126
61	Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. Journal of Infectious Diseases, 2003, 188, 1433-1443.	1.9	121
62	Effect of Influenza Vaccination on Viral Replication and Immune Response in Persons Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral Therapy. Journal of Infectious Diseases, 2000, 181, 522-531.	1.9	120
63	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. Aids, 2007, 21, 2223-2229.	1.0	117
64	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment<subtitle>A Comparison of Different Regimen Types</subtitle>. Archives of Internal Medicine, 2007, 167, 1782.	4.3	116
65	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	5.8	112
66	Effective T-Cell Responses Select Human Immunodeficiency Virus Mutants and Slow Disease Progression. Journal of Virology, 2007, 81, 6742-6751.	1.5	109
67	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. PLoS Pathogens, 2010, 6, e1001123.	2.1	108
68	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. Aids, 2002, 16, 1967-1969.	1.0	107
69	2015 Update of the Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine, 2015, 23, 132-41.	0.1	103
70	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European caseâ€“control study using centralized ultrasensitive 454 pyrosequencing. Journal of Antimicrobial Chemotherapy, 2015, 70, 930-940.	1.3	102
71	A LCâ€“tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1057-1069.	1.2	101
72	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. Aids, 2010, 24, 2347-2354.	1.0	101

#	Article	IF	Citations
73	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 2017, 66, 297-303.	1.8	101
74	Update of the drug resistance mutations in HIV-1: December 2010. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 156-63.	2.9	98
75	The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. Aids, 2009, 23, 1415-1423.	1.0	96
76	MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Journal of Experimental Medicine, 2011, 208, 439-454.	4.2	95
77	Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain, 2006, 129, 1872-1883.	3.7	94
78	Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection. PLoS Medicine, 2006, 3, e441.	3.9	92
79	Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. Journal of Experimental Medicine, 2011, 208, 1419-1433.	4.2	92
80	Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 197-203.	0.9	91
81	Adverse events of raltegravir and dolutegravir. Aids, 2017, 31, 1853-1858.	1.0	91
82	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. Frontiers in Immunology, 2018, 9, 486.	2.2	91
83	TheHCP5Singleâ€Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir. Journal of Infectious Diseases, 2008, 198, 864-867.	1.9	90
84	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. Journal of Infectious Diseases, 2011, 203, 246-257.	1.9	89
85	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 28-35.	0.9	86
86	Update of the drug resistance mutations in HIV-1: December 2009. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2009, 17, 138-45.	2.9	86
87	In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. Journal of Virology, 2007, 81, 8793-8808.	1.5	85
88	Inferring Epidemic Contact Structure from Phylogenetic Trees. PLoS Computational Biology, 2012, 8, e1002413.	1.5	85
89	Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. PLoS ONE, 2010, 5, e13310.	1.1	84
90	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. Clinical Infectious Diseases, 2011, 53, 1271-1279.	2.9	84

#	Article	IF	Citations
91	HIV RNA in plasma rebounds within days during structured treatment interruptions. Aids, 2003, 17, 195-199.	1.0	82
92	HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell Counts. PLoS Medicine, 2007, 4, e96.	3.9	81
93	Reliability formula & limit law of the failure time ofÂâ€œm-consecutive-k-out-of-n:F systemâ€• Top, 2008, 16, 62-72.	1.1	81
94	Update of the Drug Resistance Mutations in HIV-1. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2008, 16, 138-45.	2.9	79
95	Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression. PLoS ONE, 2010, 5, e11079.	1.1	78
96	Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. Aids, 2012, 26, 193-205.	1.0	78
97	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. Antiviral Therapy, 2011, 16, 535-545.	0.6	77
98	Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12266-12270.	3.3	76
99	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology, 2004, 326, 113-129.	1.1	76
100	Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. Journal of Virology, 2005, 79, 8454-8469.	1.5	76
101	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2014, 58, 285-294.	2.9	75
102	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. Journal of Infectious Diseases, 2011, 204, 1095-1103.	1.9	74
103	Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. Aids, 2004, 18, 1951-1953.	1.0	73
104	Efavirenz Intoxication Due to Slow Hepatic Metabolism. Clinical Infectious Diseases, 2005, 40, e22-e23.	2.9	73
105	Productive Human Immunodeficiency Virus Type 1 Infection in Peripheral Blood Predominantly Takes Place in CD4/CD8 Double-Negative T Lymphocytes. Journal of Virology, 2007, 81, 9693-9706.	1.5	72
106	Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5169-5172.	3.3	70
107	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 2022, 51, 33-34j.	0.9	69
108	Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds. PLoS Pathogens, 2015, 11, e1004722.	2.1	68

#	Article	IF	Citations
109	Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. Clinical Infectious Diseases, 2015, 61, 1013-1021.	2.9	67
110	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. Annals of Internal Medicine, 2021, 174, 758-767.	2.0	66
111	Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut, 2015, 64, 813-819.	6.1	65
112	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. Virus Evolution, 2018, 4, vey007.	2.2	64
113	Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrobial Agents and Chemotherapy, 2006, 50, 1773-1779.	1.4	63
114	Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology, 2009, 387, 98-108.	1.1	62
115	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. Aids, 2010, 24, 1177-1183.	1.0	62
116	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. Antiviral Therapy, 2002, 7, 91-103.	0.6	62
117	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. Journal of Infectious Diseases, 2015, 212, 28-38.	1.9	61
118	Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. Antiviral Therapy, 2004, 9, 85-95.	0.6	61
119	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 2009, 50, 1017-1029.	3.6	60
120	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 2011, 60, 1506-1519.	6.1	60
121	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2016, 62, 115-122.	2.9	60
122	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. Aids, 2015, 29, 2195-2200.	1.0	58
123	Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. Aids, 2006, 20, 35-40.	1.0	57
124	Cellular Viral Rebound after Cessation of Potent Antiretroviral Therapy Predicted by Levels of Multiply Spliced HIVâ€1 RNA Encodingnef. Journal of Infectious Diseases, 2004, 190, 1979-1988.	1.9	56
125	Estimating the net contribution of interleukinâ€28B variation to spontaneous hepatitis C virus clearance. Hepatology, 2011, 53, 1446-1454.	3.6	56
126	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121.	2.9	56

#	Article	IF	Citations
127	Glancing behind virus load variation in HIV-1 infection. Trends in Microbiology, 2003, 11, 499-504.	3.5	55
128	Next-Generation Sequencing of HIV-1 RNA Genomes: Determination of Error Rates and Minimizing Artificial Recombination. PLoS ONE, 2013, 8, e74249.	1.1	55
129	Using an Epidemiological Model for Phylogenetic Inference Reveals Density Dependence in HIV Transmission. Molecular Biology and Evolution, 2014, 31, 6-17.	3.5	55
130	HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection. Journal of Virology, 2003, 77, 13146-13155.	1.5	54
131	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. Clinical Infectious Diseases, 2011, 53, 1143-1152.	2.9	53
132	Disentangling Human Tolerance and Resistance Against HIV. PLoS Biology, 2014, 12, e1001951.	2.6	53
133	Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathogens, 2018, 14, e1006895.	2.1	53
134	Residual HIV-RNA Levels Persist for Up to 2.5 Years in Peripheral Blood Mononuclear Cells of Patients on Potent Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2000, 16, 1135-1140.	0.5	52
135	Stable virulence levels in the HIV epidemic of Switzerland over two decades. Aids, 2006, 20, 889-894.	1.0	52
136	CD8+ T Cells Are Activated in an Antigen-Independent Manner in HIV-Infected Individuals. Journal of Immunology, 2014, 192, 1732-1744.	0.4	52
137	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clinical Infectious Diseases, 2016, 62, 1310-1317.	2.9	52
138	Efficient Suppression of Minority Drugâ€Resistant HIV Type 1 (HIVâ€1) Variants Present at Primary HIVâ€1 Infection by Ritonavirâ€Boosted Protease Inhibitorâ€“Containing Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 1063-1071.	1.9	51
139	In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers. Journal of Virology, 2008, 82, 1591-1599.	1.5	50
140	Successful Treatment with Miltefosine of Disseminated Cutaneous Leishmaniasis in a Severely Immunocompromised Patient Infected with HIV-1. Clinical Infectious Diseases, 2005, 40, e120-e124.	2.9	49
141	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. PLoS ONE, 2013, 8, e77691.	1.1	49
142	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV,the, 2022, 9, e474-e485.	2.1	48
143	HIV sensitivity to neutralization is determined by target and virus producer cell properties. Aids, 2009, 23, 1659-1667.	1.0	47
144	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2016, 214, 399-402.	1.9	47

#	Article	IF	Citations
145	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	13.7	47
146	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, e2194-e2202.	2.9	47
147	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 397-404.	0.9	46
148	Entry and Transcription as Key Determinants of Differences in CD4 T-Cell Permissiveness to Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2004, 78, 10747-10754.	1.5	46
149	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood, 2004, 104, 1784-1792.	0.6	46
150	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 2010, 59, 1252-1258.	6.1	46
151	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS ONE, 2011, 6, e27463.	1.1	46
152	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, 2016, 13, 62.	0.9	45
153	Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology, 2008, 5, 107.	0.9	44
154	Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Do Not Predict Viral Growth and Clearance Rates during Structured Intermittent Antiretroviral Therapy. Journal of Virology, 2002, 76, 10169-10176.	1.5	43
155	Longâ€Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatmentâ€“Experienced Patients in Switzerland. Clinical Infectious Diseases, 2009, 48, 979-987.	2.9	43
156	Evidence for Positive Selection Driving the Evolution of HIV-1 env under Potent Antiviral Therapy. Virology, 2001, 284, 250-258.	1.1	42
157	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42
158	HIV-1 p24 Antigen Is a Significant Inverse Correlate of CD4 T-Cell Change in Patients With Suppressed Viremia Under Long-Term Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 292-299.	0.9	41
159	Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study. Antiviral Therapy, 2015, 20, 165-175.	0.6	41
160	Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases. Genes, 2019, 10, 661.	1.0	41
161	High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children. Microorganisms, 2021, 9, 642.	1.6	41
162	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. Journal of Virology, 2005, 79, 9026-9037.	1.5	40

#	Article	IF	Citations
163	Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. Journal of Medical Virology, 2006, 78, 1003-1010.	2.5	40
164	Failure to Detect Xenotropic Murine Leukemia Virusâ€“Related Virus in Blood of Individuals at High Risk of Bloodâ€Borne Viral Infections. Journal of Infectious Diseases, 2010, 202, 1482-1485.	1.9	40
165	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 2012, 56, 2959-2966.	1.4	39
166	Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells. Retrovirology, 2012, 9, 27.	0.9	39
167	A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022, 375, 540-545.	6.0	39
168	Identification of Siglec-1 null individuals infected with HIV-1. Nature Communications, 2016, 7, 12412.	5.8	38
169	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biology, 2017, 15, e2001855.	2.6	38
170	Attenuated and Nonproductive Viral Transcription in the Lymphatic Tissue of HIVâ€1â€“Infected Patients Receiving Potent Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 189, 273-285.	1.9	37
171	Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting. PLoS Pathogens, 2011, 7, e1002321.	2.1	37
172	The IFNL3/4 Î”G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. Aids, 2014, 28, 1885-1889.	1.0	37
173	High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. Clinical Infectious Diseases, 2018, 66, 735-742.	2.9	37
174	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Molecular Biology and Evolution, 2018, 35, 27-37.	3.5	37
175	Drug Resistance Mutations during Structured Treatment Interruptions. Antiviral Therapy, 2003, 8, 411-415.	0.6	37
176	Risk Factors for and Outcome of Hyperlactatemia in HIV-Infected Persons: Is There a Need for Routine Lactate Monitoring?. Clinical Infectious Diseases, 2005, 41, 721-728.	2.9	36
177	Positive In Vivo Selection of the HIVâ€1 Envelope Protein gp120 Occurs at Surfaceâ€Exposed Regions. Journal of Infectious Diseases, 2007, 196, 313-320.	1.9	36
178	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. International Journal of Epidemiology, 2014, 43, 887-896.	0.9	36
179	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genetics in Medicine, 2016, 18, 814-822.	1.1	36
180	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. Medicine (United States), 2017, 96, e5849.	0.4	36

#	Article	IF	Citations
181	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. Nature Communications, 2021, 12, 6703.	5.8	36
182	Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antiviral Therapy, 2002, 7, 91-103.	0.6	36
183	Factors Associated with the Emergence of K65R in Patients with HIVâ€1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. Clinical Infectious Diseases, 2008, 46, 1299-1309.	2.9	35
184	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1102-1112.	1.9	35
185	Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2015, 2, ofv077-ofv077.	0.4	35
186	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV,the, 2021, 8, e711-e722.	2.1	35
187	Treatment-Induced Decline of Human Immunodeficiency Virus-1 p24 and HIV-1 RNA in Lymphoid Tissue of Patients with Early Human Immunodeficiency Virus-1 Infection. American Journal of Pathology, 2000, 156, 1973-1986.	1.9	34
188	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. Journal of Infectious Diseases, 2016, 214, 599-606.	1.9	34
189	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. Journal of Virological Methods, 2010, 165, 151-160.	1.0	33
190	Higher Selection Pressure from Antiretroviral Drugs in Vivo Results in Increased Evolutionary Distance in HIV-1 pol. Virology, 1999, 259, 154-165.	1.1	32
191	Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. Journal of Clinical Immunology, 2002, 22, 363-374.	2.0	32
192	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatmentâ€“Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	2.9	32
193	Aortic Homograft Endocarditis Caused by Rhodotorula mucilaginosa. Infection, 2003, 31, 181-183.	2.3	31
194	Gonococcal Tonsillar Infectionâ€”A Case Report and Literature Review. Infection, 2003, 31, 362-365.	2.3	31
195	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE, 2007, 2, e173.	1.1	31
196	Precise Identification of a Human Immunodeficiency Virus Type 1 Antigen Processing Mutant. Journal of Virology, 2007, 81, 2031-2038.	1.5	30
197	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virusâ€“coinfected Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 68, 569-576.	2.9	30
198	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo. Journal of Virology, 2014, 88, 763-767.	1.5	29

#	Article	IF	Citations
199	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infectious Diseases, 2015, 15, 382.	1.3	29
200	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Journal of Experimental Medicine, 2018, 215, 1589-1608.	4.2	29
201	Directex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8+ T lymphocyte activation in response to therapeutic manipulation of virus load. European Journal of Immunology, 2001, 31, 1115-11121.	1.6	28
202	Antiretroviral Treatment and Osteonecrosis in Patients of the Swiss HIV Cohort Study: A Nested Case-Control Study. AIDS Research and Human Retroviruses, 2004, 20, 909-915.	0.5	28
203	HLAâ€Bw4Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1921-1925.	2.9	28
204	African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. Aids, 2009, 23, 1269-1276.	1.0	28
205	Divergent effects of cell environment on HIV entry inhibitor activity. Aids, 2009, 23, 1319-1327.	1.0	28
206	A Framework for Inferring Fitness Landscapes of Patient-Derived Viruses Using Quasispecies Theory. Genetics, 2015, 199, 191-203.	1.2	28
207	Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1. PLoS ONE, 2016, 11, e0148459.	1.1	28
208	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	2.7	28
209	Antibacterial Effects of Antiretrovirals, Potential Implications for Microbiome Studies in HIV. Antiviral Therapy, 2018, 23, 91-94.	0.6	28
210	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.4	28
211	HIVâ€1 Superinfection in an HIVâ€2â€“Infected Woman with Subsequent Control of HIVâ€1 Plasma Viremia. Clinical Infectious Diseases, 2009, 48, e117-e120.	2.9	27
212	Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIVâ€1 Reverse Transcriptase. Journal of Infectious Diseases, 2010, 201, 1054-1062.	1.9	27
213	High-Throughput Sequencing of Human Immunoglobulin Variable Regions with Subtype Identification. PLoS ONE, 2014, 9, e111726.	1.1	27
214	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. Drug Metabolism and Disposition, 2015, 44, 151-161.	1.7	27
215	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 2016, 22, 191-200.	2.8	27
216	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	1.9	27

#	Article	IF	Citations
217	Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. PLoS Pathogens, 2017, 13, e1006255.	2.1	27
218	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Scientific Reports, 2022, 12, 577.	1.6	27
219	HIVâ€1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 51, 620-628.	2.9	26
220	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical Infectious Diseases, 2022, 75, e585-e593.	2.9	26
221	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	3.9	26
222	Equal Amounts of Intracellular and Virionâ€Enclosed Hepatitis C Virus RNA Are Associated with Peripheralâ€Blood Mononuclear Cells In Vivo. Journal of Infectious Diseases, 2006, 194, 1713-1723.	1.9	25
223	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. American Journal of Epidemiology, 2014, 179, 1514-1525.	1.6	25
224	A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations. Journal of Molecular Biology, 2016, 428, 238-250.	2.0	25
225	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	0.7	25
226	Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked. Journal of Virology, 2008, 82, 3834-3842.	1.5	24
227	Mortality from suicide among people living with HIV and the general Swiss population: 1988â€2017. Journal of the International AIDS Society, 2019, 22, e25339.	1.2	24
228	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. Journal of Infectious Diseases, 2019, 220, 91-99.	1.9	24
229	HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 250-256.	0.9	23
230	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 24-31.	0.9	23
231	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. Aids, 2013, 27, 203-210.	1.0	23
232	Molecular Analyses Define VÎ±7.2-JÎ±33+ MAIT Cell Depletion in HIV Infection. Medicine (United States), 2015, 94, e1134.	0.4	23
233	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases, 2017, 64, 1275-1278.	2.9	23
234	Population pharmacokinetics of dolutegravir: influence of drugâ€“drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 2690-2697.	1.3	23

#	Article	IF	Citations
235	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitorâ€“Based Antiretroviral Treatment. Clinical Infectious Diseases, 2021, 73, e2134-e2141.	2.9	23
236	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLâ€™HIV trial. PLoS Medicine, 2020, 17, e1003421.	3.9	23
237	Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. PLoS Pathogens, 2017, 13, e1006313.	2.1	23
238	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection in vivo. Antiviral Therapy, 2003, 8, 97-104.	0.6	23
239	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. Antiviral Therapy, 2003, 8, 443-454.	0.6	23
240	Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. Aids, 2002, 16, 2317-2322.	1.0	22
241	Biphasic decline of CD4 cell count during scheduled treatment interruptions. Aids, 2005, 19, 439-441.	1.0	22
242	Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution. Methods in Ecology and Evolution, 2015, 6, 67-82.	2.2	22
243	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. Medicine (United States), 2016, 95, e5094.	0.4	22
244	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. Journal of Experimental Medicine, 2019, 216, 2071-2090.	4.2	22
245	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. Journal of Infectious Diseases, 2020, 222, 637-645.	1.9	22
246	Development and validation of a multiplex UHPLCâ€MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. Journal of Mass Spectrometry, 2020, 55, e4506.	0.7	22
247	A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. Aids, 2003, 17, 1487-1492.	1.0	21
248	Acute Cytomegalovirus Colitis Presenting during Primary HIV Infection: an Unusual Case of an Immune Reconstitution Inflammatory Syndrom. Clinical Infectious Diseases, 2008, 46, e38-e40.	2.9	21
249	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. PLoS ONE, 2011, 6, e27903.	1.1	21
250	How effectively can HIV phylogenies be used to measure heritability?. Evolution, Medicine and Public Health, 2013, 2013, 209-224.	1.1	21
251	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4+ T cells. Scientific Reports, 2016, 6, 24157.	1.6	21
252	Large-scale inference of conjunctive Bayesian networks. Bioinformatics, 2016, 32, i727-i735.	1.8	21

#	Article	IF	Citations
253	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	1.1	21
254	Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Medicine, 2009, 10, 647-656.	1.0	20
255	Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. Infection, 2010, 38, 423-426.	2.3	20
256	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. Aids, 2014, 28, 2231-2239.	1.0	20
257	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. Journal of Infectious Diseases, 2015, 212, 578-584.	1.9	20
258	On the potential of a shortâ€term intensive intervention to interrupt HCV transmission in HIVâ€positive men who have sex with men: A mathematical modelling study. Journal of Viral Hepatitis, 2018, 25, 10-18.	1.0	20
259	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	0.9	19
260	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology, 2013, 9, e1003203.	1.5	19
261	Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells. PLoS Computational Biology, 2014, 10, e1003871.	1.5	19
262	Editorial Commentary: The Irreversibility of HIV Drug Resistance. Clinical Infectious Diseases, 2015, 61, 837-839.	2.9	19
263	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clinical Infectious Diseases, 2019, 69, 1489-1497.	2.9	19
264	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ¯ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	1.0	18
265	Antibody responses in primary HIV-1 infection. Current Opinion in HIV and AIDS, 2008, 3, 45-51.	1.5	18
266	In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells. Molecular and Cellular Proteomics, 2017, 16, S108-S123.	2.5	18
267	OMIPâ€047: Highâ€Dimensional phenotypic characterization of B cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 592-596.	1.1	18
268	Analysis of Restriction Fragment Length Polymorphism and Ribotyping of Multiresistant Stenotrophomonas maltophilia Isolated from Persisting Lung Infection in a Cystic Fibrosis Patient. Scandinavian Journal of Infectious Diseases, 1995, 27, 499-502.	1.5	17
269	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 464-471.	0.9	17
270	A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Reports, 2012, 2012, bcr0320125973-bcr0320125973.	0.2	17

#	Article	IF	Citations
271	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. PLoS ONE, 2014, 9, e114111.	1.1	17
272	A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Scientific Reports, 2016, 6, 32251.	1.6	17
273	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. Journal of Immunological Methods, 2018, 454, 48-58.	0.6	17
274	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evolution, 2018, 4, vey024.	2.2	17
275	Sequence Clusters in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Are Associated with Subsequent Virological Response to Antiretroviral Therapy. Journal of Infectious Diseases, 1999, 180, 1043-1049.	1.9	16
276	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PLoS ONE, 2012, 7, e50307.	1.1	16
277	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domainâ€™s exceptional capacity for sequence variation. Retrovirology, 2014, 11, 75.	0.9	16
278	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 2014, 210, 1555-1561.	1.9	16
279	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. Retrovirology, 2017, 14, 33.	0.9	16
280	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. ELife, 2017, 6, .	2.8	16
281	Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015â€“16. Journal of Antimicrobial Chemotherapy, 2018, 73, 1917-1929.	1.3	16
282	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab032.	0.4	16
283	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€“Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	2.9	16
284	Phylodynamics on local sexual contact networks. PLoS Computational Biology, 2017, 13, e1005448.	1.5	16
285	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. PLoS ONE, 2012, 7, e37983.	1.1	15
286	Cluster of Leptospirosis Acquired Through River Surfing in Switzerland. Open Forum Infectious Diseases, 2015, 2, ofv102.	0.4	15
287	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. Scientific Reports, 2016, 6, 27580.	1.6	15
288	HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages. PLoS ONE, 2015, 10, e0132127.	1.1	15

#	Article	IF	Citations
289	Pulmonary Toxoplasmosis, a Rare but Severe Manifestation of a Common Opportunistic Infection in Late HIV Presenters: Report of Two Cases. Infection, 2010, 38, 141-144.	2.3	14
290	HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 566-573.	0.9	14
291	Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domainÂ¿s exceptional capacity for sequence variation. Retrovirology, 2014, 11, 75.	0.9	14
292	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clinical Infectious Diseases, 2022, 75, 1723-1731.	2.9	14
293	HIVâ€1 replication activates CD4 ⁺ T cells with specificities for persistent herpes viruses. EMBO Molecular Medicine, 2010, 2, 231-244.	3.3	13
294	Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 2011, 12, 299-307.	1.0	13
295	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. Aids, 2018, 32, 327-335.	1.0	13
296	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunctionâ€"A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 227-232.	0.9	13
297	OUP accepted manuscript. Clinical Infectious Diseases, 2019, 68, 561-568.	2.9	13
298	Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antiviral Therapy, 2003, 8, 97-104.	0.6	13
299	Liver failure after long-term nucleoside antiretroviral therapy. Lancet, The, 2001, 358, 759-760.	6.3	12
300	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 397-404.	0.9	12
301	HIV replication elicits little cytopathic effects in vivo: Analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death. Journal of Medical Virology, 2006, 78, 1141-1146.	2.5	12
302	Impact of HIVâ€1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogueâ€"Based Regimens in Antiretroviral Therapy (ART)â€"Naive and ARTâ€Experienced Patients. Journal of Infectious Diseases, 2007, 196, 1180-1190.	1.9	12
303	Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 377-385.	0.9	12
304	Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infectious Diseases, 2012, 12, 88.	1.3	12
305	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipoatrophy. Journal of Infectious Diseases, 2011, 203, 620-624.	1.9	11
306	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIVâ€"HCV-Coinfected Individuals. Antiviral Therapy, 2014, 19, 149-159.	0.6	11

#	Article	IF	Citations
307	Human papillomavirus antibody response following HAART initiation among MSM. Aids, 2017, 31, 561-569.	1.0	11
308	Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs. Microorganisms, 2021, 9, 1700.	1.6	11
309	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. Journal of Clinical Medicine, 2021, 10, 295.	1.0	11
310	No Effect of Pegylated Interferon-Î± on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. Journal of Infectious Diseases, 2018, 217, 1883-1888.	1.9	10
311	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. Clinical Infectious Diseases, 2020, 70, 297-303.	2.9	10
312	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. Clinical Infectious Diseases, 2021, 72, 2175-2183.	2.9	10
313	Drug resistance mutations during structured treatment interruptions. Antiviral Therapy, 2003, 8, 411-5.	0.6	10
314	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. Antiviral Therapy, 2006, 11, 305-314.	0.6	10
315	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 2009, 14, 771-779.	0.6	9
316	Minority K65R Variants and Early Failure of Antiretroviral Therapy in HIV-1â€“infected Eritrean Immigrant. Emerging Infectious Diseases, 2011, 17, 1966-1968.	2.0	9
317	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2011, 203, 791-797.	1.9	9
318	Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 105-112.	0.9	9
319	New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment, Sustained Viral Suppression, and Immune Restoration. Open Forum Infectious Diseases, 2014, 1, ofu005.	0.4	9
320	Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. Clinical Infectious Diseases, 2014, 59, 1386-1393.	2.9	9
321	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 2015, 16, 297-306.	1.0	9
322	The Orientation of HIV-1 gp120 Binding to the CD4 Receptor Differentially Modulates CD4+ T Cell Activation. Journal of Immunology, 2015, 194, 637-649.	0.4	9
323	Prescription of Postexposure Prophylaxis for HIV-1 in the Emergency Room: Correct Transmission Risk Assessment Remains Challenging. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 359-366.	0.9	9
324	Clusters of Sexual Behavior in Human Immunodeficiency Virusâ€“positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. Clinical Infectious Diseases, 2019, 70, 416-424.	2.9	9

#	Article	IF	Citations
325	IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients. Aids, 2019, 33, 1719-1727.	1.0	9
326	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Journal of Antimicrobial Chemotherapy, 2019, 74, 468-472.	1.3	9
327	Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation. Viruses, 2020, 12, 1330.	1.5	9
328	Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	5.5	9
329	Assessing relative COVID-19 mortality: a Swiss population-based study. BMJ Open, 2021, 11, e042387.	0.8	9
330	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines ComirnatyÂ® and COVID-19 mRNA Vaccine ModernaÂ®. Trials, 2021, 22, 724.	0.7	9
331	Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. Nature Communications, 2021, 12, 6705.	5.8	9
332	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. Open Forum Infectious Diseases, 2022, 9, .	0.4	9
333	Spontaneous Splenic Rupture as Manifestation of the Immune Reconstitution Inflammatory Syndrome in an HIV Type 1 Infected Patient with Tuberculosis. Infection, 2009, 37, 163-165.	2.3	8
334	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. Journal of Translational Medicine, 2011, 9, 14.	1.8	8
335	The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. Aids, 2015, 29, 1803-1810.	1.0	8
336	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infectious Diseases, 2018, 5, ofy078.	0.4	8
337	Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. Scientific Reports, 2018, 8, 10204.	1.6	8
338	The influence of human genetic variation on Epsteinâ€“Barr virus sequence diversity. Scientific Reports, 2021, 11, 4586.	1.6	8
339	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	1.1	8
340	Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 2003, 8, 443-54.	0.6	8
341	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Aids, 2007, 21, 2201-2207.	1.0	7
342	Predictors of CD4+ T-Cell Counts of HIV Type 1â€“Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7

#	Article	IF	Citations
343	Simple Estimation of Incident HIV Infection Rates in Notification Cohorts Based on Window Periods of Algorithms for Evaluation of Line-Immunoassay Result Patterns. PLoS ONE, 2013, 8, e71662.	1.1	7
344	Role of MicroRNA Modulation in the Interferon-Î±/Ribavirin Suppression of HIV-1 In Vivo. PLoS ONE, 2014, 9, e109220.	1.1	7
345	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. Clinical Infectious Diseases, 2021, 73, e2070-e2076.	2.9	7
346	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 517-524.	0.9	7
347	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. JCI Insight, 2021, 6, .	2.3	7
348	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 492-499.	1.3	7
349	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Medicine, 2020, 17, e1003397.	3.9	7
350	High Rates of Asymptomatic Mycoplasma genitalium Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	7
351	Aortic homograft endocarditis caused by Cardiobacterium hominis and complicated by agranulocytosis due to ceftriaxone. BMJ Case Reports, 2010, 2010, bcr0420102894-bcr0420102894.	0.2	6
352	Efavirenz intoxication due to a new CYP2B6 constellation. Antiviral Therapy, 2013, 18, 735-738.	0.6	6
353	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv257.	1.3	6
354	Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. Aids, 2016, 30, 1923-1933.	1.0	6
355	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. Aids, 2018, 32, 2759-2765.	1.0	6
356	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	1.9	6
357	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 314-320.	0.9	6
358	Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19. PLoS Computational Biology, 2021, 17, e1008609.	1.5	6
359	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. Journal of Infectious Diseases, 2021, 224, 2053-2063.	1.9	6
360	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 61-69.	0.9	6

#	Article	IF	Citations
361	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. PLoS Computational Biology, 2021, 17, e1009529.	1.5	6
362	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biology, 2020, 18, e3000963.	2.6	6
363	Pharmacokinetics of an HIV-1 gp120-specific chimeric antibody in patients with HIV-1 disease. Biotherapy (Dordrecht, Netherlands), 1993, 6, 205-215.	0.7	5
364	Impact of TNFÎ±, LTÎ±, FcÎ³RII and complement receptor on HIV-1 trapping in lymphoid tissue from HIV-infected patients. Aids, 2000, 14, 2661-2669.	1.0	5
365	Expansion of interferonâ€Îˆ³â€šecreting <scp>HIV</scp>â€špecific T cells during successful antiretroviral therapy. HIV Medicine, 2013, 14, 241-246.	1.0	5
366	Protease inhibitors to treat hepatitis <scp>C</scp> in the <scp>S</scp>wiss <scp>HIV C</scp>ohort <scp>S</scp>tudy: high efficacy but low treatment uptake. HIV Medicine, 2015, 16, 599-607.	1.0	5
367	Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e114-e117.	0.9	5
368	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. International Journal of Cancer, 2020, 147, 757-765.	2.3	5
369	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nature Communications, 2020, 11, 5542.	5.8	5
370	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. Journal of Infectious Diseases, 2020, 224, 1198-1208.	1.9	5
371	Coronary Artery Diseaseâ€“Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, 1597-1604.	2.9	5
372	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 306-316.	1.9	5
373	Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals. Aids, 2022, 36, 205-214.	1.0	5
374	Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antiviral Therapy, 2009, 14, 953-964.	0.6	4
375	Outcomes of Patients on Dual-Boosted PI Regimens: Experience of the Swiss HIV Cohort Study. AIDS Research and Human Retroviruses, 2010, 26, 1239-1246.	0.5	4
376	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
377	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. Antiviral Therapy, 2019, 24, 343-353.	0.6	4
378	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. Haematologica, 2021, 106, 2233-2241.	1.7	4

#	Article	IF	Citations
379	Assessing relative COVID-19 mortality during the second wave: a prospective Swiss population-based study. BMJ Open, 2021, 11, e051164.	0.8	4
380	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 1592-1600.	1.9	4
381	A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. Antiviral Therapy, 2006, 11, 305-14.	0.6	4
382	2010 Guidelines for Antiretroviral Treatment of HIV From the International AIDS Societyâ€“USA Panelâ€”Reply. JAMA - Journal of the American Medical Association, 2010, 304, 1897.	3.8	3
383	Estimating the dynamics and dependencies of accumulating mutations with applications to HIV drug resistance. Biostatistics, 2015, 16, 713-726.	0.9	3
384	Reply to correspondence â€˜Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a â€œstochasticâ€•processâ€™ by Gonzalez et al., Retrovirology 2017. Retrovirology, 2017, 14, 14.	0.9	3
385	Can Directionality of HIV Transmission be Predicted by Next-Generation Sequencing Data?. Journal of Infectious Diseases, 2018, 220, 1393-1395.	1.9	3
386	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013â€“2017, in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2020, 71, 637-644.	2.9	3
387	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. Viruses, 2020, 12, 1241.	1.5	3
388	A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells. Viruses, 2021, 13, 404.	1.5	3
389	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. ELife, 2021, 10, .	2.8	3
390	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. Clinical Infectious Diseases, 2022, 74, 1468-1475.	2.9	3
391	561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. Open Forum Infectious Diseases, 2020, 7, S345-S346.	0.4	3
392	Subacute, tetracycline-responsive, granulomatous osteomyelitis in an adult man, consistent with Q fever infection. BMJ Case Reports, 2015, 2015, bcr2015212426.	0.2	3
393	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. Journal of Infectious Diseases, 2022, 225, 1581-1591.	1.9	3
394	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.4	3
395	Impact of Latent Tuberculosis on Diabetes. Journal of Infectious Diseases, 2022, 225, 2229-2234.	1.9	3
396	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, , .	1.9	3

#	Article	IF	Citations
397	Association between specific HIV-1 Env traits and virologic control in vivo. Infection, Genetics and Evolution, 2010, 10, 365-372.	1.0	2
398	<scp>HLA</scp>â€<scp>Bw4</scp> identifies a population of <scp>HIV</scp>â€infected patients with an increased capacity to control viral replication after structured treatment interruption. HIV Medicine, 2012, 13, 589-595.	1.0	2
399	Mining for pairs: shared clinic visit dates identify steady <scp>HIV</scp>â€positive partnerships. HIV Medicine, 2017, 18, 667-676.	1.0	2
400	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 72, 1413-1421.	2.9	2
401	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. Nature Communications, 2021, 12, 1219.	5.8	2
402	Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center. Antimicrobial Resistance and Infection Control, 2021, 10, 51.	1.5	2
403	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. Journal of Infectious Diseases, 2021, , .	1.9	2
404	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C. PLoS Computational Biology, 2021, 17, e1008363.	1.5	2
405	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980â€“2018. Antiviral Therapy, 2020, 25, 43-54.	0.6	2
406	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. Journal of Infectious Diseases, 2022, 226, 1057-1068.	1.9	2
407	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. Viruses, 2022, 14, 784.	1.5	2
408	Spinal Osteomyelitis Caused by Candida glabrata. Infectious Diseases in Clinical Practice, 1998, 7, 112-116.	0.1	1
409	A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression. Retrovirology, 2011, 8, .	0.9	1
410	Response to Calcagno Comment on â€œHigher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluidâ€• Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, e14-e15.	0.9	1
411	Gut commensal microbes do not represent a dominant antigenic source for continuous CD4⁺ Tâ€cell activation during HIVâ€1 infection. European Journal of Immunology, 2015, 45, 3107-3113.	1.6	1
412	HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance. Journal of Infectious Diseases, 2016, 214, 1289-1291.	1.9	1
413	MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma. Open Forum Infectious Diseases, 2018, 5, ofy052.	0.4	1
414	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load. Virus Evolution, 2022, 8, veac022.	2.2	1

#	Article	IF	Citations
415	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. Viruses, 2022, 14, 406.	1.5	1
416	Probing of viral diversity by global haplotype prediction. , 2013, , .		0
417	Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatmentâ€"Reply. JAMA - Journal of the American Medical Association, 2018, 320, 2154.	3.8	0
418	Reply to Ambrosioni et al. Clinical Infectious Diseases, 2019, 68, 1977-1978.	2.9	0
419	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 508-515.	0.9	0
420	Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab046.	0.4	0
421	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravirâ€based regimens in SIMPL'HIV clinical trial. British Journal of Clinical Pharmacology, 2021, 87, 4455-4460.	1.1	0
422	Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring. Statistical Communications in Infectious Diseases, 2022, 14, .	0.2	0
423	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	0
424	Title is missing!. , 2020, 18, e3000963.		0
425	Title is missing!. , 2020, 18, e3000963.		0
426	Title is missing!. , 2020, 18, e3000963.		0
427	Title is missing!. , 2020, 18, e3000963.		0
428	Title is missing!. , 2020, 18, e3000963.		0
429	Title is missing!. , 2020, 18, e3000963.		0
430	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
431	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
432	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0

#	Article	IF	Citations
433	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
434	Title is missing!. , 2020, 17, e1003421.		0
435	Title is missing!. , 2020, 17, e1003421.		0
436	Title is missing!. , 2020, 17, e1003421.		0
437	Title is missing!. , 2020, 17, e1003421.		0
438	Title is missing!. , 2020, 17, e1003421.		0
439	Title is missing!. , 2020, 17, e1003421.		0
440	Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPLâ€™HIV Trial). Frontiers in Virology, 0, 2, .	0.7	0